Intellia Therapeutics Inc. [NASDAQ: NTLA] stock went on an upward path that rose over 3.84% on Tuesday, amounting to a one-week price increase of more than 4.48%.
Over the last 12 months, NTLA stock rose by 115.59%. The one-year Intellia Therapeutics Inc. stock forecast points to a potential upside of 18.04. The average equity rating for NTLA stock is currently 2.10, trading closer to a bullish pattern in the stock market.
Get 12 free stock market lessons delivered to your email from Investor's Business Daily, the leader in investing education for over 35 years. We’ll cover the basics of better investing and show you how to give yourself an edge in the market.
GET FREE LESSON outside the norm.
The market cap for the stock reached $1.49 billion, with 53.37 million shares outstanding and 48.92 million shares in the current float. Compared to the average trading volume of 875.10K shares, NTLA stock reached a trading volume of 1122460 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Intellia Therapeutics Inc. [NTLA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NTLA shares is $31.04 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NTLA stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for Intellia Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 27, 2020. The new note on the price target was released on October 14, 2020, representing the official price target for Intellia Therapeutics Inc. stock. Previously, the target price had yet another raise to $33, while Goldman analysts kept a Buy rating on NTLA stock.
The Average True Range (ATR) for Intellia Therapeutics Inc. is set at 1.81, with the Price to Sales ratio for NTLA stock in the period of the last 12 months amounting to 29.39. The Price to Book ratio for the last quarter was 3.86, with the Price to Cash per share for the same quarter was set at 7.46.
NTLA Stock Performance Analysis:
Intellia Therapeutics Inc. [NTLA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.48. With this latest performance, NTLA shares gained by 19.89% in over the last four-week period, additionally plugging by 77.53% over the last 6 months – not to mention a rise of 115.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NTLA stock in for the last two-week period is set at 57.62, with the RSI for the last a single of trading hit 59.09, and the three-weeks RSI is set at 57.33 for Intellia Therapeutics Inc. [NTLA]. The present Moving Average for the last 50 days of trading for this stock 21.91, while it was recorded at 24.62 for the last single week of trading, and 17.86 for the last 200 days.
Insight into Intellia Therapeutics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Intellia Therapeutics Inc. [NTLA] shares currently have an operating margin of -246.78. Intellia Therapeutics Inc.’s Net Margin is presently recorded at -230.92.
Return on Total Capital for NTLA is now -37.57, given the latest momentum, and Return on Invested Capital for the company is -35.52. Return on Equity for this stock declined to -36.34, with Return on Assets sitting at -29.21. When it comes to the capital structure of this company, Intellia Therapeutics Inc. [NTLA] has a Total Debt to Total Equity ratio set at 6.81. Additionally, NTLA Total Debt to Total Capital is recorded at 6.37, with Total Debt to Total Assets ending up at 5.50. Long-Term Debt to Equity for the company is recorded at 4.68, with the Long-Term Debt to Total Capital now at 4.38.
Reflecting on the efficiency of the workforce at the company, Intellia Therapeutics Inc. [NTLA] managed to generate an average of -$368,641 per employee. Receivables Turnover for the company is 7.09 with a Total Asset Turnover recorded at a value of 0.13.Intellia Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.50 and a Current Ratio set at 7.50.
NTLA Stock EPS
With the latest financial reports released by the company, Intellia Therapeutics Inc. posted -0.49/share EPS, while the average EPS was predicted by analysts to be reported at -0.62/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 21.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NTLA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Intellia Therapeutics Inc. go to 30.00%.
Intellia Therapeutics Inc. [NTLA] Insider Position Details
There are presently around $1,373 million, or 83.20% of NTLA stock, in the hands of institutional investors. The top three institutional holders of NTLA stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 11,403,379, which is approximately 11.369% of the company’s market cap and around 0.90% of the total institutional ownership; SUMITOMO MITSUI TRUST HOLDINGS, INC., holding 6,195,189 shares of the stock with an approximate value of $157.61 million in NTLA stocks shares; and NIKKO ASSET MANAGEMENT AMERICAS, INC., currently with $157.31 million in NTLA stock with ownership of nearly -12.8% of the company’s market capitalization.
Positions in Intellia Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 106 institutional holders increased their position in Intellia Therapeutics Inc. [NASDAQ:NTLA] by around 10,230,159 shares. Additionally, 49 investors decreased positions by around 2,769,189 shares, while 27 investors held positions by with 40,964,496 shares. The mentioned changes placed institutional holdings at 53,963,844 shares, according to the latest SEC report filing. NTLA stock had 47 new institutional investments in for a total of 4,220,360 shares, while 20 institutional investors sold positions of 444,799 shares during the same period.